View older revisions Content changed at 2021-04-05, 1400/01/16

Protocol summary

Study aim
Evaluation of the melatonin and N-acetyl cysteine role on colistin-induced acute nephrotoxicity in critically ill patients
Design
The randomized, parallel-group, controlled clinical trial, among 51 patients (17 patients in each group of melatonin, N-acetyl cysteine, or control) was designed. Card shuffling was used for randomization.
Settings and conduct
This randomized clinical trial was designed to evaluate the effect of melatonin (3 mg tablet twice daily for 5 days) and N-acetyl cysteine in the prevention of colistin-induced acute renal injury and compared it with control group. This study was conducted among critically ill patients admitted to the intensive care unit (ICU) of Alzahra hospital in Isfahan, Iran. Renal injury was assessed according to urinary neutrophil gelatinase-associated lipocalin (NGAL) and serum creatinine changes.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Adult patients (more than 18 years) who received intravenous colistin Creatinine clearance ≥ 45 ml/min at study recruitment Oral tolerance to the drug Exclusion criteria: Receiving intravenous collistin or melatonin for at least 2 weeks before study recruitment Acute kidney injury before study recruitment
Intervention groups
Melatonin group: Administration of melatonin tablet (3 mg) twice daily for 5 days N-acetyl cysteine group: Administration of NAC tablet (600 mg) twice daily for 5 days Control group: No intervention was conducted in addition to standard care to prevent colistin-induced nephrotoxicity
Main outcome variables
Urinary level of neutrophil gelatinasee-associated lipocalin, serum Creatinin level

General information

Reason for update
The high prevalence of N-acetyl cysteine (NAC) prescription for critically ill patients in our study setting, could be an important confounding factor for final analysis due to NAC's potential benefit of reducing the urinary neutrophil gelatinase-associated lipocalin (NGAL) level. Therefore, we decided to compare its effect on colistin-induced nephrotoxicity prevention in the separated group.
Acronym
IRCT registration information
IRCT registration number: IRCT20150221021159N3
Registration date: 2020-06-23, 1399/04/03
Registration timing: registered_while_recruiting

Last update: 2021-04-05, 1400/01/16
Update count: 1
Registration date
2020-06-23, 1399/04/03
Registrant information
Name
Shadi Farsaei
Name of organization / entity
Isfahan University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 31 3792 2618
Email address
farsaei@pharm.mui.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2018-12-09, 1397/09/18
Expected recruitment end date
2020-09-22, 1399/07/01
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of the protective effect of melatonin and N-acetyl cysteine on colistin-induced nephrotoxicity in critically ill patients: A randomized, controlled clinical trial
Public title
The effect of melatonin and N-acetyl cysteine on colistin-associated nephrotoxicity
Purpose
Prevention
Inclusion/Exclusion criteria
Inclusion criteria:
Adult patients (more than 18 years) who received intravenous colistin. Creatinine clearance ≥ 45 ml/min at study recruitment Oral tolerance to the drug
Exclusion criteria:
Receiving intravenous collistin or melatonin for at least 2 weeks before study recruitment Acute kidney injury before study recruitment
Age
From 18 years old
Gender
Both
Phase
3
Groups that have been masked
No information
Sample size
Target sample size: 51
Randomization (investigator's opinion)
Randomized
Randomization description
Numbers from 1 to 51 were written on the separated cards, and 17 cards were assigned to each group of melatonin, N-acetyl cysteine, and control. These cards were placed in the box, and one card was selected randomly from these shuffled cards for each eligible patient on the study recruitment day. According to the number of the chosen card, patients were categorized into a specific group.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Isfahan University of Medical Sciences
Street address
Department of clinical pharmacy and pharmacy practice, faculty of pharmacy, Isfahan University of Medical Sciences, Hezar Jarib Ave. Isfahan University of Medical Sciences.
City
Isfahan
Province
Isfehan
Postal code
۷۳۴۶۱-۸۱۷۴۶
Approval date
2018-12-05, 1397/09/14
Ethics committee reference number
IR.MUI.MED.REC.1397.151

Health conditions studied

1

Description of health condition studied
Acute kidney failure
ICD-10 code
N17.9
ICD-10 code description
Acute kidney failure, unspecified

Primary outcomes

1

Description
Acute kidney failure based on changes of urinary Neutrophil gelatinase-associated lipoccalin (NGAL) and serum creatinine levels.
Timepoint
Measurement of urinary NGAL and serum creatinine at the initial of study (before initiation of colistin or intervention) and 5 days after intervention
Method of measurement
ELISA Kit

Secondary outcomes

empty

Intervention groups

1

Description
First intervention group: Melatonin tablets made in nature made company are administered orally at the dose of 3 mg twice daily for 5 days, on the same date of starting colistin.
Category
Prevention

2

Description
Control group: No intervention was conducted in addition to standard care to prevent colistin-induced nephrotoxicity
Category
N/A

3

Description
Second intervention group: N-acetyl cysteine tablet are administered orally at the dose of 600 mg twice daily for 5 days, on the same date of starting colistin.
Category
Prevention

Recruitment centers

1

Recruitment center
Name of recruitment center
AlZahra hospital
Full name of responsible person
Shadi Farsaei
Street address
No.53, 29th Alley , Chahar Bagh Paeen Ave., Isfahn, Iran
City
Isfahan
Province
Isfehan
Postal code
8148614481
Phone
+98 31 3792 7071
Email
farsaei@pharm.mui.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shaghayegh Haghjou Javanmard
Street address
Bldg No. 4, Vice chancellery research and technology, Isfahan University of Medical Sciences and Health Services, Hezar Jerib Ave., Isfahan, Iran
City
Isfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3668 8138
Email
research@mui.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Esfahan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shadi Farsaei
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Clinical pharmacy and pharmaceutical practices department, Pharmacy faculty, Isfahan university of medical sciences, Hezar jerib Ave., Isfahan, Iran
City
Isfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3792 7071
Email
Farsaei@pharm.mui.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shadi Farsaei
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Clinical pharmacy and pharmaceutical practices department, Pharmacy faculty, Isfahan university of medical sciences, Hezar jerib Ave., Isfahan, Iran
City
Isfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3792 7071
Email
Farsaei@pharm.mui.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shadi Farsaei
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Clinical pharmacy and pharmaceutical practices department, Pharmacy faculty, Isfahan university of medical sciences, Hezarjerib St.
City
Isfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3792 7071
Email
Farsaei@pharm.mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...